title: The response of patients with Duchenne's muscular dystrophy to neuromuscular blockade with vecuronium.
abstract: BACKGROUND
  The authors hypothesized that patients with Duchenne's muscular dystrophy (DMD) are more sensitive to nondepolarizing muscle relaxants.
  
  
  METHODS
  Eight children with DMD and eight healthy children having orthopedic procedures were studied. Anesthesia consisted of thiopental, 60% nitrous oxide in 40% oxygen, and intravenous fentanyl and midazolam. Using electromyography, the ulnar nerve was stimulated and the electromyographic train-of-four ratio (TOFr) of the first dorsal interosseous muscle was recorded every 60 s. After baseline TOFr recording, all patients received 50 microg/kg vecuronium and the TOFr at 3 min was compared. Vecuronium (10 microg/kg) was then administered every minute until TOFr was < or =0.1. The TOFr was followed until TOFr was > or =0.01. Then 10 microg/kg of vecuronium were administered to maintain TOFr < or = 0.1. At the conclusion of the procedure, TOFr was allowed to recover to 0.25, and then neostigmine and glycopyrrolate were administered. Data are presented as medians and ranges.
  
  
  RESULTS
  The initial dose of vecuronium resulted in greater TOFr depression in patients with DMD than in controls (0.14 vs. 0.86). Less vecuronium was needed to produce TOFr < or = 0.1 in the patients with DMD than in the control patients (55 microg/kg vs. 95 microg/kg). Recovery time for the TOFr to > or =0.1 after the initial dose was longer in the patients with DMD than in the controls (28 vs. 20 min; P = 0.03), and the maintenance dose of vecuronium was less in patients with DMD (0.6 vs. 1.3 microg x kg[-1] min[-1]; P < 0.01). The time for TOFr recovery from 0.1 to 0.25 was 36 min in the patients with DMD and 6 min in the controls (P < 0.01). After neostigmine, the TOFr was 1.0 in the controls and 0.91 (P = 0.03) in the patients with DMD.
  
  
  CONCLUSIONS
  There is increased sensitivity to vecuronium from neuromuscular blockade in patients with DMD.
authors.affiliation: Department of Anesthesia, Harvard Medical School and Children's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: D G
authors.initials: DG
authors.lastname: Ririe
authors.forename: F
authors.initials: F
authors.lastname: Shapiro
authors.forename: N F
authors.initials: NF
authors.lastname: Sethna
mesh_terms: D000293:Adolescent; D019162:Anesthetics, Combined; D018686:Anesthetics, Intravenous; D016022:Case-Control Studies; D002648:Child; D004305:Dose-Response Relationship, Drug; D004576:Electromyography; D005283:Fentanyl; D006801:Humans; D008297:Male; D008874:Midazolam; D009136:Muscular Dystrophies / Q000503:physiopathology*; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D013874:Thiopental; D014673:Vecuronium Bromide / Q000494:pharmacology*
chemical_list: D019162:Anesthetics, Combined; D018686:Anesthetics, Intravenous; D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D013874:Thiopental; D008874:Midazolam; D005283:Fentanyl